Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Sana Biotechnology (SANA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Sana Biotechnology (SANA – Research Report) with bullish sentiments.

Eli Lilly & Co (LLY)

In a report issued on June 23, Asad Haider from Goldman Sachs maintained a Buy rating on Eli Lilly & Co, with a price target of $883.00. The company’s shares closed last Wednesday at $792.62.

According to TipRanks.com, Haider is a 2-star analyst with an average return of 0.8% and a 41.7% success rate. Haider covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Johnson & Johnson, and Merck & Company.

Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $999.57, which is a 28.3% upside from current levels. In a report issued on June 9, Citi also maintained a Buy rating on the stock with a $1190.00 price target.

See today’s best-performing stocks on TipRanks >>

Sana Biotechnology (SANA)

In a report issued on June 23, Samantha Semenkow from Citi maintained a Buy rating on Sana Biotechnology, with a price target of $15.00. The company’s shares closed last Wednesday at $2.90, close to its 52-week low of $1.52.

According to TipRanks.com, Semenkow ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.6% and a 27.6% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, MoonLake Immunotherapeutics, and Allogene Therapeutics.

Currently, the analyst consensus on Sana Biotechnology is a Strong Buy with an average price target of $7.33, implying a 146.8% upside from current levels. In a report issued on June 23, H.C. Wainwright also maintained a Buy rating on the stock with a $11.00 price target.

Read More on LLY:

• Eli Lilly’s Donanemab Study: A Potential Game-Changer in Alzheimer’s Treatment
• Eli Lilly’s New Diabetes Drug Study: What Investors Need to Know
• Eli Lilly’s Promising Study on Lebrikizumab for Atopic Dermatitis
• Eli Lilly’s Promising Alzheimer’s Study: A Potential Game-Changer?
• Eli Lilly’s Tirzepatide Study: A Potential Game-Changer in Adolescent Obesity Treatment